Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
SCHD vs VHT: Weighing a Diversified Dividend ETF Against a Health Care Specialist

SCHD vs VHT: Weighing a Diversified Dividend ETF Against a Health Care Specialist

Key Takeaways

  • SCHD is a low-cost, diversified dividend strategy spanning multiple sectors, while VHT is a concentrated, single-sector bet on U.S. health care.
  • SCHD charges a razor-thin 0.06% expense ratio; VHT costs slightly more at roughly 0.09%, though both are among the cheapest funds in their categories.
  • SCHD holds about 100 dividend-paying large caps across energy, consumer staples, and health care, whereas VHT's roughly 420–440 holdings sit almost entirely within one industry.
  • VHT carries meaningful single-stock concentration, with Eli Lilly (LLY) alone near 13% of assets; SCHD's largest position is closer to 4–5%.
  • Risk profiles differ sharply: SCHD's below-market beta (around 0.77–0.79) reflects its defensive tilt, while VHT's sector purity exposes it to health care policy and patent cycles.
  • Tickeron AI Verdict: VHT — based on sector momentum, trend consistency, and structural exposure, the AI framework currently favors VHT over SCHD.

Why These Two Funds Stand Apart

Investors comparing SCHD and VHT are not choosing between two near-identical products. These funds represent fundamentally different ways of pursuing defensive, income-oriented exposure. SCHD is a broad, dividend-focused portfolio that draws income from multiple industries, while VHT is a pure-play vehicle concentrated in a single, economically resilient sector. They compete for the same investor dollar — those seeking lower volatility and steady total return — but deliver it through very different paths. Understanding that structural gap is essential before evaluating either fund's relative positioning in the current market cycle. I also checked sector overlaps using Tickeron’s AI Screener to see how the holdings line up across industries.

SCHD: A Broad Dividend-Focused Approach

SCHD is a passively managed exchange-traded fund (ETF) that tracks the Dow Jones U.S. Dividend 100 Index. The underlying index screens for companies with strong dividend track records, solid cash flow, and healthy balance sheets, emphasizing both dividend yield and dividend sustainability. The fund typically holds around 100–104 stocks, weighted by market capitalization with caps to limit concentration.

Top holdings recently included Merck & Co. (MRK), Abbott Laboratories (ABT), Amgen (AMGN), Coca-Cola (KO), Home Depot (HD), Chevron (CVX), ConocoPhillips (COP), UnitedHealth Group (UNH), Procter & Gamble (PG), and Texas Instruments (TXN). Sector exposure skews defensive: energy and consumer staples each approach 19–20%, health care roughly 16%, with industrials and financials filling out the balance. Its 0.06% expense ratio makes it one of the cheapest dividend funds available, and the index is reconstituted annually. From what I see, the emphasis on sustainability gives it a steady profile worth monitoring.

VHT: Concentrated Exposure to Health Care

VHT is a passively managed ETF that tracks the MSCI US Investable Market Health Care 25/50 Index. The fund provides broad, market-cap-weighted exposure to large-, mid-, and small-cap U.S. health care companies, holding roughly 420–440 securities. It is one of the most comprehensive, lowest-cost ways to own the entire U.S. health care complex in a single position.

Nearly 100% of the portfolio sits in the health care sector, spanning pharmaceuticals, biotechnology, medical devices, health insurers, and managed care. Top holdings are heavily weighted toward mega-cap pharma: Eli Lilly (LLY) at roughly 13%, Johnson & Johnson (JNJ) near 9%, AbbVie (ABBV) around 6%, followed by Merck (MRK), UnitedHealth Group (UNH), Thermo Fisher Scientific (TMO), Amgen (AMGN), Abbott Laboratories (ABT), Gilead Sciences (GILD), and Pfizer (PFE). The fund charges a 0.09% expense ratio and uses full replication to mirror its benchmark. I’m watching this closely because the concentration in a few names can amplify both upside and downside moves.

Different Thematic Currents at Play

The two funds sit in very different thematic currents. SCHD's fortune is tied to the broader dividend and value complex — energy prices, consumer staples pricing power, and the level of interest rates that shape how investors value income-producing equities. When yield becomes scarce or defensive rotation accelerates, SCHD tends to attract capital flows.

VHT, by contrast, is driven by health care-specific catalysts. Innovation in GLP-1 weight-loss and diabetes therapies has propelled select mega-caps, while an aging global population underpins durable demand for pharmaceuticals and managed care. At the same time, the sector carries idiosyncratic risks: drug-pricing reform, regulatory scrutiny, patent expirations, and clinical-trial outcomes. Macro factors such as interest-rate expectations and merger-and-acquisition activity in biotech also shape sentiment. Both funds offer defensive characteristics, but VHT concentrates that defense in a single, innovation-driven industry.

Recent Performance and Positioning

In recent market cycles, the two funds have diverged meaningfully. SCHD's value and dividend orientation has lagged growth-heavy benchmarks, as its energy, staples, and financials weightings offered income but limited participation in technology-led rallies. Its below-market beta has kept drawdowns relatively shallow, reinforcing its role as a stability-oriented sleeve rather than a momentum vehicle.

VHT has benefited from strong performance among its largest holdings. Mega-cap pharmaceutical and health care names such as Eli Lilly, Johnson & Johnson, and AbbVie have posted robust gains over the trailing year, lifting the fund's returns and supporting consistent relative momentum. However, this concentration cuts both ways: a setback in any top holding can weigh disproportionately on the fund. From what I see, VHT has exhibited stronger trend consistency in recent months, while SCHD has offered lower volatility and higher income but weaker price momentum.

Using Tickeron AI Tools in My Process

One resource I turn to regularly is Tickeron’s AI Screener. It lets me filter ETFs and stocks by technical patterns, fundamentals, trends, volatility, and AI-driven signals, which helps surface relative strength and breakout ideas more efficiently than manual checks. For side-by-side evaluations like this one, the tool provides a structured way to compare momentum before making allocation decisions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SCHD, VHT

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


SCHD in upward trend: 10-day moving average moved above 50-day moving average on October 22, 2026

The 10-day moving average for SCHD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on SCHD as a result. In 67 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for SCHD just turned positive on November 13, 2026. Looking at past instances where SCHD's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.

SCHD moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHD advanced for three days, in 265 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 282 of 364 cases where SCHD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Bearish Trend Analysis

The 10-day RSI Indicator for SCHD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 30 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

SCHD broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are Chevron Corp (NYSE:CVX), Coca-Cola Company (NYSE:KO), Procter & Gamble Company (NYSE:PG), Merck & Co (NYSE:MRK), Unitedhealth Group (NYSE:UNH), Home Depot (NYSE:HD), Texas Instruments (NASDAQ:TXN), Amgen (NASDAQ:AMGN), PepsiCo (NASDAQ:PEP), Abbott Laboratories (NYSE:ABT).

Industry description

The investment seeks to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100™ Index. To pursue its goal, the fund generally invests in stocks that are included in the index. The index is designed to measure the performance of high dividend yielding stocks issued by U.S. companies that have a record of consistently paying dividends, selected for fundamental strength relative to their peers, based on financial ratios. The fund will invest at least 90% of its net assets in these stocks.

Market Cap

The average market capitalization across the Schwab US Dividend Equity ETF (SCHD) ETF is 57.94B. The market cap for tickers in the group ranges from 363.12M to 417.06B. CVX holds the highest valuation in this group at 417.06B. The lowest valued company is AMSF at 363.12M.

High and low price notable news

The average weekly price growth across all stocks in the Schwab US Dividend Equity ETF (SCHD) ETF was 3%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was 16%. NXST experienced the highest price growth at 10%, while FLO experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the Schwab US Dividend Equity ETF (SCHD) ETF was -21%. For the same stocks of the ETF, the average monthly volume growth was -16% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 42
Price Growth Rating: 42
SMR Rating: 42
Profit Risk Rating: 57
Seasonality Score: 10 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.